Vyant Bio to Deliver a Live Presentation at the Skyline Signature Series™ on Thursday, September 8, 2022
Vyant Bio, Inc. (Nasdaq: VYNT) announced its participation in the Skyline Signature Series on September 8, 2022. This live, interactive online presentation will allow investors to engage with the company in real-time. Vyant Bio focuses on drug discovery for neurodevelopmental and neurodegenerative disorders utilizing a proprietary CNS platform that integrates human-derived organoid models and machine learning. Investors are required to pre-register for the event, which aims to facilitate effective communication with a curated audience of financial professionals.
- Participation in the interactive Skyline Signature Series enhances visibility among investors.
- Proprietary CNS drug discovery platform leverages advanced technology for improved drug development.
- None.
-Invites individual and institutional investors, as well as advisors and analysts, to attend this real-time, interactive presentation at the Skyline Signature Series™
CHERRY HILL, N.J., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company’s proprietary central nervous system (“CNS”) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Today, Vyant Bio announced that it will be presenting at the Skyline Signature Series™ on Thursday, September 8, 2022.
This will be a live, interactive online event where investors are invited to ask the company questions in real-time. All investors must pre-register.
| Event: | Skyline Signature Series™ |
| Date: | Thursday, September 8, 2022 |
| Time: | 12:00 PM ET |
| Registration: | https://us02web.zoom.us/webinar/register/WN_EX1HMiZkQS69MwIAoytifw |
| Audio Dial-In: | +1 301-715-8592, Webinar ID: 87824712545# |
ABOUT THE SKYLINE SIGNATURE SERIES™
The Skyline Signature Series provides public companies with a convenient and effective forum to communicate their story to a diverse audience of financial professionals through live virtual presentations. Our financial community participants are carefully curated and qualified by SCCG. Each individual must register and be individually vetted by SCCG to attend so that presenters are ensured of a high quality, informed, and diverse audience of financial professionals.
Skyline Corporate Communications Group, LLC will be compensated by Vyant Bio for providing investor relations services relating to the Company’s securities. Please see the 17(b) Disclaimer and Disclosure Statement here: www.skylineccg.com/disclosures
ABOUT SKYLINE CORPORATE COMMUNICATIONS GROUP, LLC
Skyline Corporate Communications Group, LLC, with offices in Boston and New York City, is an investor relations and corporate communications firm that provides strategic messaging and investor communications consulting services for public corporations. Skyline delivers strategic assistance for companies in the financial markets and investment community by effectively communicating their corporate message and competitive advantages. Our team has worked with scores of U.S.-listed public companies worldwide across diverse industries and various market caps. We have experience with shareholder activism and crisis communications and also work with late-stage private companies to help prepare them to enter the public marketplace.
For additional information on Skyline CCG, please visit: www.skylineccg.com
ABOUT VYANT BIO, INC.
Vyant Bio, Inc. (“Vyant Bio” or the “Company”) (Nasdaq: VYNT) is an innovative biotechnology company focused on identifying unique biological targets and novel and repurposed therapeutics. Vyant Bio has built a platform of therapeutics seeking to treat neurodevelopmental and neurodegenerative diseases, with current programs targeting Rett Syndrome (“Rett”), CDKL5 Deficiency Disorders (“CDD”), and Parkinson’s Disease. The Company’s approach to drug discovery integrates human-derived biology with artificial intelligence and machine learning technologies to de-risk candidate selection, with the goal of improving the potential effectiveness of drugs discovered earlier in the development cycle. Vyant Bio’s management believes that drug discovery needs to progressively shift to more efficient methods as the widely used models for predicting safe and effective drugs have under-performed, as evidenced by the significant time and cost of bringing novel drugs to patients. By combining sophisticated data science capabilities with highly functional human cell derived disease models, Vyant Bio seeks to leverage its current ability to screen and test therapeutic candidates, and create a unique approach to assimilating data that supports decision making iteratively throughout the discovery phase of drug development to identify both novel and repurposed CNS therapeutic candidates.
For more information, please visit or follow Vyant Bio at:
Internet: www.vyantbio.com
LinkedIn: https://www.linkedin.com/company/vyant-bio
Twitter: @VyantBio
Forward Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to Vyant Bio, Inc.’s expectations regarding future financial and/or operating results, the efficacy of our drug screening and discovery process, and potential for our services, future revenue or growth in this press release constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” and “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in our attempts to discover drug candidates, partner with pharmaceutical and other biotechnology companies, achieve profitability, adapt to the global coronavirus pandemic, raise capital to meet our liquidity needs, and other risks discussed in the Vyant Bio, Inc. Form 10-K for the year ended December 31, 2021, and any subsequent filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Vyant Bio disclaims any obligation to update these forward-looking statements.
Investor Contact:
Skyline Corporate Communications Group, LLC
Scott Powell, President
One Rockefeller Plaza, 10th Floor
New York, NY 10020 USA
Office: (646) 893-5835 x2
Email: info@skylineccg.com
###
FAQ
What is Vyant Bio's participation in the Skyline Signature Series?
What technologies does Vyant Bio use in drug discovery?
When is the Skyline Signature Series event for Vyant Bio?
How can investors register for the Skyline Signature Series?
